Weekly Headlines: Aldeyra Reports New Phase 3 Data for DED Drug Candidate Reproxalap episode artwork

EPISODE · Aug 14, 2024 · 5 MIN

Weekly Headlines: Aldeyra Reports New Phase 3 Data for DED Drug Candidate Reproxalap

from Eyewire News: The Podcast · host Eyewire News

Aldeyra Reports New Phase 3 Data for DED Drug Candidate Reproxalap • Lensar Receives European Approval for ALLY System • Lenz Therapeutics Submits NDA for Presbyopia Eye Drop Learn more about your ad choices. Visit megaphone.fm/adchoices

NOW PLAYING

Weekly Headlines: Aldeyra Reports New Phase 3 Data for DED Drug Candidate Reproxalap

0:00 5:17

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

Frequently Asked Questions

How long is this episode of Eyewire News: The Podcast?

This episode is 5 minutes long.

When was this Eyewire News: The Podcast episode published?

This episode was published on August 14, 2024.

What is this episode about?

Aldeyra Reports New Phase 3 Data for DED Drug Candidate Reproxalap • Lensar Receives European Approval for ALLY System • Lenz Therapeutics Submits NDA for Presbyopia Eye Drop Learn more about your ad choices. Visit megaphone.fm/adchoices

Can I download this Eyewire News: The Podcast episode?

Yes, you can download this episode by clicking the download button on the episode player, or subscribe to the podcast in your preferred podcast app for automatic downloads.
URL copied to clipboard!